enGene (ENGN) vs. Its Competitors Critical Review

enGene (NASDAQ:ENGN) is one of 449 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare enGene to similar businesses based on the strength of its analyst recommendations, dividends, risk, earnings, profitability, institutional ownership and valuation.

Valuation & Earnings

This table compares enGene and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
enGene	N/A	$104.74 million	-3.94
enGene Competitors	$159.28 million	-$18.96 million	-57.87

enGene’s rivals have higher revenue, but lower earnings than enGene. enGene is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

enGene has a beta of -0.63, meaning that its stock price is 163% less volatile than the S&P 500. Comparatively, enGene’s rivals have a beta of 1.24, meaning that their average stock price is 24% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for enGene and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	0	6	0	3.00
enGene Competitors	755	2455	5770	67	2.57

enGene presently has a consensus target price of $34.40, indicating a potential upside of 435.83%. As a group, “Biotechnology” companies have a potential upside of 16.95%. Given enGene’s stronger consensus rating and higher probable upside, research analysts plainly believe enGene is more favorable than its rivals.

Profitability

This table compares enGene and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-63.25%	-5.65%
enGene Competitors	-11,569.30%	-124.58%	-24.31%

Insider and Institutional Ownership

64.2% of enGene shares are owned by institutional investors. Comparatively, 31.5% of shares of all “Biotechnology” companies are owned by institutional investors. 13.7% of enGene shares are owned by company insiders. Comparatively, 22.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dividends

enGene pays an annual dividend of $1.58 per share and has a dividend yield of 24.6%. enGene pays out -97.0% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 3.1% and pay out 5,072.0% of their earnings in the form of a dividend. enGene is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.

Summary

enGene beats its rivals on 11 of the 15 factors compared.

enGene Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.